Downstream processing

[HIGHLIGHTS]- Advanced 7 drug and biologics discovery programs achieving pre-clinical milestones by generating recombinant fusion proteins to facilitate SPR-based affinity/kinetic analysis, HTS assay development, structural-based lead optimization, etc.- Established 6 technical platforms to enable production of challenging recombinant and introduction of 5 discovery programs for portfolio expansion.- Communicated and presented interpreted data to address complex scientific question & solution, resource allocation and prioritization in cross-functional matrixes.[SCIENTIFIC CONTRIBUTIONS]- Strategized and performed expression of various classes of recombinant proteins implicated in neurodegenerative diseases from a variety of host systems. - Designed and performed chromatographic strategies using AKTA or batch method.- Enabled to improve productivities and scalabilities (from 5ml to 24L) of recombinants.- Performed analytical characterization as QCs of deliverables in timely effective manner.- Deployed database and sequence analysis software for construct design.- Conducted aseptic technique in cell culture and cell-based studies.- Fully complied with electronic data retention and update on in-house database.

- Combinatorial Effect of Src/Syk Tyrosine Kinase and Calpain Protease Inhibitors on Human Platelets for Antithrombotic Therapy- Gα13 Switch Region 2 Relieves Talin Autoinhibition to Activate αIIbβ3 Integrin- Structural Determinants of the Talin Head Domain Recognition by Gα13 Switch Region 2- Selective Dipeptidyl Peptidase Inhibitor-Induced Tumor Pyroptosis for Treatment of Acute Myeloid Leukemia

- Performed multi-steps total synthesis of 4 projects and doubled the yield at gram scale.- Organized and carried out comprehensive trainings on synthetic procedures, NMR and MS.